Press Releases

Press Releases

Date Title and Summary Additional Formats
Sep 20, 2018 Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease on September 25-27 in New York City Cantor Fitzgerald Global Healthcare Conference on October 1-3 in New York City CORAL GABLES, Fla. , Sept. 20, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.
Aug 29, 2018 Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 20th Annual Global Investment Conference

CORAL GABLES, Fla. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
Aug 20, 2018 Catalyst Pharmaceuticals Appoints Dr. Stanley Iyadurai as Vice President of Clinical Development

CORAL GABLES, Fla. , Aug. 20, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
Aug 07, 2018 Catalyst Pharmaceuticals Announces Second Quarter 2018 Financial Results and Provides Corporate Update

--Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating,
Aug 06, 2018 Catalyst Pharmaceuticals Expands Commercial Leadership Team

Augments Medical Affairs Team with 3 Additional Medical Science Liaisons CORAL GABLES, Fla. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare
Aug 01, 2018 Catalyst Pharmaceuticals to Hold Second Quarter Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 8th, 2018

CORAL GABLES, Fla. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
Jun 13, 2018 Catalyst Pharmaceuticals Appoints Daniel J. Brennan as Chief Commercial Officer

CORAL GABLES, Fla. , June 13, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
May 31, 2018 Catalyst Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

CORAL GABLES, Fla. , May 31, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
May 29, 2018 Catalyst Pharmaceuticals Announces FDA Acceptance of NDA and Priority Review Status for Firdapse® (Amifampridine Phosphate) for Lambert-Eaton Myasthenic Syndrome

--PDUFA Date Set for November 28, 2018 CORAL GABLES, Fla. , May 29, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular
May 09, 2018 Catalyst Pharmaceuticals Announces First Quarter 2018 Financial Results and Provides Corporate Update

--Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla. , May 09, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating,

Displaying 1 - 10 of 20